Swisher SG , Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB Jr, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M
Most published combination data involves cagrilintide paired with semaglutide (the combination known as CagriSema, being developed by Novo Nordisk)
These findings are not trivial, but they exist several steps removed from human application
The urate crystals often exist silently in tissues for long periods between symptoms
That is the entire basis for the CagriSema combination therapy that has generated so much excitement in clinical trials
Urine samples of these women were collected at the hospital at different time points per day, after one (pregnant woman 1), two (pregnant women 2, 3 and 4), or four (pregnant woman 5) APAP intakes
